// App-Quantinova.ai

: The CXCR4 Antagonist, BL8040, Is Highly Active Against Human T-ALL in Preclinical Models

Researchers

Presenter

  • Jun Xia

Principal Investigators

  • Matthew RM Jotte

  • Stephanie Sun

  • Geoffrey L. Uy

  • Abi Vainstein

  • Ella Sorani

  • Osnat Bohana-Kashtan

  • Stephen Shaw

  • Daniel C. Link

Medical Centers

  • Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA

  • The University of Chicago Medical Center, Chicago, IL

  • Washing University, St.Louis

  • Washington University School of Medicine, St. Louis, MO

  • BioLineRx, Modiin, Israel

  • BioLineRx, Modiin, Israel

  • BioLineRx, Modiin, Israel

  • Division of Oncology, Washington University School of Medicine, St. Louis, MO

Locations

  • United States

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Hematological malignancies

  • Solid malignancies

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • B-cell lymphoma 2

  • Cluster of differentiation 45

  • C-X-C motif chemokine receptor 4

  • Stromal cell-derived factor 1

Drug/Treatment

  • Navitoclax

  • BL-8040

  • CXCL12

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • NCT02763384

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved